Colorectal Cancer Therapeutics Market Size – By Therapy (Immunotherapy, Chemotherapy), Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors), Treatment Provider (Hospitals, Specialty Clinics) & Forecast, 2024 – 2032

Colorectal Cancer Therapeutics Market Size

Colorectal Cancer Therapeutics Market size was valued at USD 12.4 billion in 2023 and is poised to expand at over 4.6% CAGR from 2024 to 2032, due to rising incidence rates, advancements in targeted and cancer immunotherapy, and enhanced screening and early detection programs. An aging global population, improved healthcare infrastructure in emerging markets, and increased healthcare expenditure further drive demand. Further, regulatory support and substantial research funding facilitate the development and rapid approval of new treatments, while precision medicine tailors’ therapies to individual genetic profiles, improving patient outcomes.
 

Colorectal cancer therapeutics refers to the range of medical treatments and interventions used to manage and treat colorectal cancer, which includes cancers of the colon and rectum. These therapeutics aim to eliminate cancer cells, reduce tumor size, prevent cancer recurrence and improve patient survival.
 

Colorectal Cancer Therapeutics Market Trends

• The increasing incidence and prevalence of colorectal cancer/oncology globally serve as a fundamental driver in the colorectal cancer therapeutics industry. Various factors contribute to this rise that include aging populations, sedentary lifestyles, unhealthy dietary habits, and genetic predispositions.
   
• This growing prevalence underscores the urgent need for effective colorectal cancer therapeutics to address the rising burden of this disease on healthcare systems and society, thereby propelling the growth of this market.
   
• Additionally, increased awareness and early detection efforts have played a crucial role. Enhanced screening programs and public health initiatives have led to earlier diagnosis of colorectal cancer, which is more treatable in its early stages, thereby increasing the demand for therapeutic interventions.
   
• Furthermore, technological advancements in colorectal cancer therapeutics have revolutionized the treatment landscape. Innovations such as targeted therapies, immunotherapies, and personalized medicine approaches have led to more effective and less toxic treatment options, thus expanding market opportunities.
   

Colorectal Cancer Therapeutics Market Analysis

Based on therapy, the market is segmented into chemotherapy, immunotherapy, and other therapies. The immunotherapy segment held over 75.7% of market share in 2023.
 

• Immunotherapies such as immune checkpoint inhibitors including pembrolizumab and nivolumab, have shown significant efficacy in treating colorectal cancer, particularly in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These therapies often result in longer-lasting responses and improved survival rates compared to traditional chemotherapy.
   
• Additionally, expedited regulatory approvals, growing clinical evidence, and increased patient awareness have all contributed to the widespread adoption of immunotherapy, consolidating its position in the market.
   

Based on cancer type, the colorectal cancer therapeutics market is divided into colorectal adenocarcinoma, gastrointestinal carcinoid tumors, and other cancer types. The colorectal adenocarcinoma segment is expected to reach USD 9.1 billion by end of 2032.
 

• Colorectal adenocarcinoma is the most common histological subtype of colorectal cancer, accounting for most cases diagnosed. As a result, there is a larger patient population requiring therapeutic interventions specifically tailored to treat adenocarcinoma.
   
• Also, extensive research and clinical trials have focused on developing targeted therapies and immunotherapies specifically designed to address the molecular intricacies of adenocarcinoma. These advancements is expected to significantly expand treatment options, thereby fostering the segment's dominance in the market.
   

Based on treatment provider, the colorectal cancer therapeutics market is classified into hospitals, specialty clinics, and cancer research centers. The hospital segment held majority of market share and is anticipated to exhibit CAGR of 4.8% through 2032.
 

• Hospitals dominate the colorectal cancer therapeutics industry due to their provision of comprehensive cancer care, access to advanced treatment technologies, and multidisciplinary approach.
   
• Moreover, hospitals are perceived as the most reliable healthcare institutions by patients, leading to a preference for seeking cancer care in hospital settings. Patients value the comprehensive care, specialized expertise, and access to advanced medical technologies offered by hospitals.
   

North America colorectal cancer therapeutics market accounted for USD 5.3 billion in 2023 and is projected to witness growth at 4.5% over the forecast timeframe.
 

• North America dominates the colorectal cancer therapeutics industry owing to its rising cancer prevalence, availability of advanced healthcare infrastructure, technological innovations, high healthcare expenditure, and favorable regulatory environment.
   
• For instance, according to the American Cancer Society, it is anticipated that 152,810 individuals in the U.S. will be diagnosed with colorectal cancer in 2024. Therefore, with an increasing number of individuals being diagnosed with colorectal cancer each year, there is a corresponding rise in demand for effective therapeutic interventions to treat the disease.
   
• Thus, the high incidence rates of colorectal cancer in the region is expected to drive the growth of this market.
   

Germany colorectal cancer therapeutics market held a significant position in Europe market.
 

• The high incidence of colorectal cancer underscores the significant impact of the disease on the German population. For instance, according to Rober Koch Institute, in Germany approximately one in every eight newly diagnosed cancer cases involves the large intestine (colon) or rectum. Similarly, in 2020, around 24,240 colorectal cases were newly diagnosed among women, while 30,530 cases were reported among men.
   
• Therefore, as a result, the market in Germany is expected to experience growth in response to this escalating prevalence.
   

Asia Pacific colorectal cancer therapeutics market is predicted to demonstrate promising growth of 5% between 2024 and 2032.
 

• With a greater focus on early detection and diagnosis, along with enhanced awareness campaigns, more patients are seeking timely medical intervention, further driving the demand for colorectal cancer therapeutics.
   
• Additionally, supportive government initiatives and favorable regulatory policies aimed at promoting healthcare innovation and accessibility are expected to bolster market growth in Asia Pacific colorectal cancer therapeutics segment.
   

Colorectal Cancer Therapeutics Market Share

The competitive landscape of the colorectal cancer therapeutics industry is marked by intense rivalry among major pharmaceutical companies and biotech firms, each striving to gain a significant foothold in the market. Key players leverage their extensive portfolios and innovative treatment approaches to maintain a competitive edge.
 

Colorectal Cancer Therapeutics Market Companies

Prominent players operating in the colorectal cancer therapeutics industry include:

• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Celleron Therapeutics
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sumitomo Pharma Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• TAIHO PHARMACEUTICAL CO., LTD
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Colorectal Cancer Therapeutics Industry News

• In November 2023, U.S. FDA approved fruquintinib of Takeda Pharmaceutical for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine. This approval is expected to help the company to strengthen its product portfolio and generate revenue.
   
• In January 2023, HUTCHMED announces license to Takeda to develop and commercialize Fruquintinib outside China. This strategic initiative helped the company to expand its geographic presence and revenue.
   

The colorectal cancer therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy

• Chemotherapy
• Immunotherapy
• Other therapies

Market, By Cancer Type

• Colorectal adenocarcinoma
• Gastrointestinal carcinoid tumors
• Other cancer types

Market, By Treatment Provider

• Hospitals
• Specialty clinics
• Cancer research centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa